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ABSTRACT OF THESIS

THE UTILITY OF THE UNIFIED PROTOCOL IN TREATING BORDERLINE
PERSONALITY DISORDER
Borderline personality disorder (BPD) is characterized by maladaptive levels
across three personality domains: Neuroticism, (low) Agreeableness, and (low)
Conscientiousness. The Unified Protocol (UP) is a transdiagnostic treatment that targets
neuroticism and has demonstrated promising effects with BPD. However, not all
individuals with BPD respond to UP treatment. The aim of the current study was to explore
the extent to which the UP is an efficacious treatment for BPD symptoms. This study
represents a secondary analysis of a clinical trial in which the UP was the study treatment;
data from the full sample and a subset of nine participants who likely met criteria for BPD
were included. First, we explored within-group changes in general BPD symptoms, along
with specific symptom domains. Improvements in total BPD symptoms were not observed
in the full sample, whereas the UP resulted in moderate overall BPD symptom
improvement among participants with BPD. Contrary to expectations, emotional
difficulties did not exhibit larger effects than other domains. We also explored differences
in within-person change in BPD scores during treatment based on patients’ FFM profiles
at baseline. Change on BPD symptoms was not predicted by a typical BPD FFM profile.
Possible explanations for the results and limitations were discussed.
KEYWORDS: borderline personality disorder, Unified Protocol
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CHAPTER 1. INTRODUCTION
1.1

Background
The Unified Protocol (UP; Barlow et al., 2011) is a transdiagnostic

treatment that targets common mechanisms implicated in the development and
maintenance of a range of emotional disorders (e.g., anxiety, depressive, and related
disorders; Barlow, 1991; Cassiello-Robbins et al., 2020). Specifically, the UP targets the
emotional disorder functional model (Bullis et al., 2019) in which (1) frequently occurring
negative emotions (neuroticism) are (2) met with aversive reactions that, in turn, lead to
(3) efforts to avoid or suppress emotional experiences. Aversive/avoidant reactions to
emotions paradoxically increase the frequency and intensity of negative emotional
experiences (Aldao & Nolen-Hoeksema, 2010; Cisler & Olatunji, 2012; Ottenbreit et al.,
2014), thereby maintaining the neurotic temperament (e.g., Sauer-Zavala et al., 2020).
Thus, the UP consists of several core treatment modules broadly aimed at extinguishing
distress in response to strong emotions (Payne et al., 2014). By targeting aversive reactions
to a wide variety of negative emotions when they occur, the UP may reduce reliance on
the avoidant coping that exacerbates negative emotionality. As negative emotions become
less frequent over time, and when these changes are sustained, these behavioral and
emotional changes may constitute decreases in neuroticism (Magidson et al., 2014).
Indeed, the UP is associated with significant decreases in aversive reactions to emotions
(Eustis et al., 2020; Sauer-Zavala et al., 2012), as well as neuroticism (Carl et al., 2014;
Sauer-Zavala et al., 2020). This treatment has also demonstrated efficacy in addressing a
range of emotional disorders, such as generalized and social anxiety disorder, bipolar
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disorder, obsessive compulsive disorder, and depressive symptoms (Cassiello-Robbins et
al., 2020; Sakiris & Berle, 2019).
The UP may also be a useful approach for individuals with borderline
personality disorder (BPD; see Sauer-Zavala et al., 2016). Specifically, Linehan (1993)
describes BPD as chiefly characterized by emotional vulnerability (i.e., emotional
intensity, reactivity, and slow return to baseline functioning) that is akin to the neurotic
temperament. Indeed, there is ample empirical evidence to suggest that individuals with
this condition demonstrate high levels of neuroticism relative to other clinical and healthy
samples (Clarkin et al., 1993; Larstone et al., 2002; Morey, 1991; Samuel & Widiger,
2008; Saulsman & Page, 2004; Widiger et al., 2013). Additionally, individuals with BPD
exhibit aversive reactions to negative emotions (the primary target of the UP) that lead to
the use of emotionally-avoidant coping strategies (Roemer et al., 2005). The actions that
constitute the behavioral dysregulation included in the diagnostic criteria for BPD (e.g.,
self-injurious behavior, substance use, risky sex, reckless spending) have been shown to
function as behavioral avoidance from unwanted negative emotions (Aldao & NolenHoeksema, 2010; Baker et al., 2004; Moore et al., 2008; Tull & Roemer, 2007; Turk et al.,
2005).
Several small studies have examined the utility of the UP for patients
diagnosed with BPD. For example, results from one study showed significant reductions
in BPD symptoms and increases in emotion-regulation capacity for four out of five patients
with mild to moderate BPD symptoms who completed a course of treatment with the UP
(Sauer-Zavala et al., 2016). Similarly, in another study, Lopez and colleagues (2015)
showed that six out of eight participants with BPD who received the UP no longer met
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diagnostic criteria for this condition at follow up. Some patients in this sample also
demonstrated improvements in co-occurring symptoms of anxiety and depression (Lopez
et al., 2019). More recently, Tonarely and colleagues (2020) described a case study using
the UP to treat an adolescent patient with borderline features. This course of treatment
resulted in a clinically significant decrease in borderline features, as well as in anxiety and
depressive symptom severity, from pre-treatment to post-treatment.
Despite the UP’s promise as a short-term treatment for BPD, some patients
in these studies did not experience clinically significant improvements in their symptoms.
For example, symptoms worsened for one of the cases in Sauer-Zavala et al.'s (2016) study.
The authors noted that this patient was more impulsive and displayed greater
suspiciousness of others relative to the rest of their sample. The authors then speculated
that the UP may not be as adept in addressing these specific symptoms of BPD. Similarly,
in Lopez and colleagues' (2015) sample, two of the eight participants continued to meet
diagnostic criteria for BPD despite demonstrating remission for comorbid panic disorder
and specific phobia diagnoses. This pattern of results suggests that UP’s emotion-focus
may be sufficient for some presentations of BPD (i.e., those with symptoms mediated by
high levels of neuroticism) but may be incomplete for others.
Differing treatment responses amongst patients with BPD may be due to
the high heterogeneity of this condition. To meet the BPD diagnosis, an individual must
endorse five out of nine diagnostic criteria (American Psychiatric Association [APA],
2013). As such, there are two hundred fifty-six possible combinations of criteria that might
render the same diagnosis and two individuals with the same diagnosis of BPD might share
only one diagnostic criterion (APA, 2013; Smits et al., 2017). Additionally, several studies
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identified specific subtypes of BPD based on DSM criteria (e.g., Hallquist & Pilkonis,
2012; Smits et al., 2017). This heterogeneity may be due to the fact that several
psychopathological mechanisms, beyond neuroticism/emotional dysfunction, have been
proposed to account for the development of BPD (e.g., insecure attachment, impulsivity);
if treatments are not engaging the maintaining factors relevant for an individual patient
with BPD, they may be less likely to respond. In addition to emotional vulnerability
described by Linehan (1993), two other constructs thought to be implicated in the etiology
of BPD are discussed below.
Some theorists contend that insecure attachment processes play a key role
in the development and maintenance of BPD (Agrawal et al., 2004; Choi-Kain et al., 2009;
Fonagy et al., 2000, 2003; Sack et al., 1996). The theory of insecure attachment in BPD
stipulates that the absence of secure caregiver bonds in childhood lies at the core of BPD
and has lifetime consequences such that adult individuals with BPD do not have the
confidence in the availability of attachment figures (e.g., friends, romantic partners),
especially when support, protection, and comfort is sought and needed (Fonagy et al.,
2003; Levy, 2005). As a result, individuals with BPD exhibit an intense need for closeness
and dependency as well as intense fears of rejection or abandonment. And even though
these individuals find close relationships important, they are acutely sensitive to subtle
events in their social environment that frequently lead to volatile relationships, isolative
behaviors, emotion intensity, and impulsivity (Scott & Pilkonis, 2018).
Additionally, several studies have implicated trait impulsivity, or the
tendency to act without careful thought, reflection, or regard for the negative and longterm consequences (Vandenbos, 2007), as an important risk mechanism for the
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development and maintenance of BPD (Bornovalova et al., 2005; Crowell et al., 2009;
Lieb et al., 2004; Links et al., 1999; Terzi et al., 2017; Turner et al., 2017). Like the
neurotic temperament, the tendency to behave impulsively is biologically-based (Coccaro
et al., 1993), and may be exacerbated during heightened emotional states (Linehan, 1993;
Stanley & Singh, 2018). In other words, when faced with intense and uncontrollable
negative affect, individuals with BPD who are high in impulsivity may engage in extreme
maladaptive behaviors, such as binge-eating, substance use, gambling, and unsafe sexual
activities (Jacob et al., 2013; Lieb et al., 2004), along with nonsuicidal self-injurious
behaviors and suicide attempts (Linehan, 1993; Siever, 2018). In this way, impulsive
behaviors serve as means to regulate extreme negative emotions which, in turn, perpetuate
the rise of negative emotions (Stanley & Singh, 2018). Thus, for some individuals with
high levels of trait impulsivity, addressing negative affect alone (i.e., without targeting
impulsive behaviors implicated in negative emotion regulation) may not significantly
reduce BPD behavioral dysfunction.
It is important to note that these proposed mechanisms for BPD (i.e.,
emotion dysfunction, attachment insecurity, impulsivity) may not be mutually exclusive.
The Five Factor Model (FFM; Costa & McCrae, 1995) of personality may provide a way
to characterize an individual’s personality-based risk. The FFM divides personality into
five dimensional traits, including extraversion, or the tendency to be outgoing and sociable
(vs. introversion), neuroticism, the frequent and intense experience of negative emotions
(vs. emotional stability), openness to experience, or the willingness to try new activities
(vs. closeness to experience), agreeableness, or the quality of being friendly and
cooperative (vs. antagonism), and conscientiousness, or the ability to evaluate
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consequences of one’s behavior (vs. impulsivity). Personality disorders are thought to
emerge as a result of extreme degrees of these traits (Widiger et al., 2009, 2013). Factor
analytic studies (e.g., Mullins-Sweatt et al., 2012) suggest that BPD may be reflected as
high levels of neuroticism and low levels of agreeableness (corresponding to the
attachment-based perspective of BPD) and conscientiousness (corresponding to trait
impulsivity observed in BPD). This personality structure of BPD is consistent with other
dimensional models of psychopathology. For example, in the alternative model of
personality disorders in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
(DSM-5; APA, 2013), BPD is characterized by facets of negative affectivity, disinhibition
(i.e., impulsivity), and psychoticism (i.e., aggression and aloofness). Similarly, in the
Hierarchical Taxonomy of Psychopathology (HiTOP; Kotov et al., 2017), BPD is
considered to be located on both the internalizing and antagonistic externalizing
spectrums.
These dimensional systems can produce a dimensional profile that can be
used to develop a personalized treatment plan based on the mechanisms maintaining an
individual patient’s BPD symptoms. For instance, a patient with elevations largely
confined to neuroticism subscales will likely benefit from the UP, whereas a patient who
also exhibits low agreeableness and conscientiousness (not explicitly targeted by the UP)
may need additional treatment components.
1.2

Current Study
The main aim of the current study was to gather preliminary evidence to

investigate the extent to which the UP is a helpful treatment for BPD using secondary data
drawn from a sequential multiple assignment randomized trial (SMART; Sauer-Zavala et

6

al., under review). Given previous pilot work exploring the UP’s effect on BPD symptoms
(reviewed above), we hypothesized that this intervention would result in significant BPD
symptom improvement among participants who likely met criteria for this condition.
Additionally, we sought to examine whether specific BPD domains would improve across
a course of care with the UP among participants who likely met criteria for BPD. Given
the UP’s focus on emotion dysfunction, we hypothesized that we would observe a larger
effect for reductions in emotional difficulties relative to identity problems, relationship
problems, and impulsivity. Lastly, we explored whether there were differences in withinperson change in BPD scores during treatment based on patients’ FFM profiles at baseline.
We hypothesized that the largest improvements following treatment with the UP would be
exhibited by individuals with FFM profiles characterized by high neuroticism and at least
moderate levels of agreeableness and conscientiousness. In contrast, we anticipated that
those with low levels of agreeableness and/or conscientiousness would demonstrate
minimal improvements following treatment with the UP.
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CHAPTER 2. METHOD
2.1

Participants
Participants included in this study were drawn from a sequential multiple

assignment randomized trial (SMART), which was designed to determine the feasibility
and efficacy of sequencing the UP modules based on individual’s strengths or weaknesses
and whether terminating the treatment prior to delivering the full package would show
comparable results to the full treatment. The SMART’s treatment-seeking participants
were recruited from the community via online advertisements and their inclusion criteria
consisted of being at least 18 years of age and having at least one of the following DSM5 (APA, 2013) diagnoses: panic disorder (PD), generalized anxiety disorder (GAD), social
anxiety disorder (SAD), obsessive-compulsive disorder (OCD), posttraumatic stress
disorder (PTSD), major depressive disorder (MDD), or persistent depressive disorder
(PDD). Participants were excluded if they experienced mania within the past year,
presented with acute suicide risk, met criteria for a substance use disorder within the past
three months, or had ever experienced delusions or hallucinations. Additionally,
participants who attended at least five sessions of cognitive behavioral therapy (CBT) in
the last five years were excluded. Participants were asked to discontinue any other
psychiatric treatment they might have been receiving before the start of the study and agree
to maintain a steady dose of their medication throughout the study participation (i.e., from
the time they consented to the study).
The parent trial included 57 participants and a subset of participants (n = 9,
15.8%), who likely met criteria for borderline personality disorder (i.e., individuals with
pre-treatment Personality Assessment Inventory-Borderline Features Subscale [PAI-BOR;
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Morey, 1991] total scores ≥ 38 [equivalent to 65T]), and provided data at all timepoints in
order to a) calculate within-person scores and b) directly compare within-person change
scores in the same sample between first and second assessments, first and third
assessments, and second and third assessments. The nine participants’ mean age was 29.22
(SD = 8.44, range: 20-47), they were mostly female (66.7%) and Caucasian (77.8%). All
participants finished high school and 66.7% of them had completed an undergraduate
degree or higher. A little over a half of participants were single and never married (55.6%)
and approximately two thirds considered themselves straight or heterosexual (66.7%). The
remaining participants from the parent study (n = 48) were 35.06 old on average (SD =
12.70, range 19-63), mostly female (66.7%) and Caucasian (77.1%). Everyone in the nonBPD sample completed high school or GED and 66.6% completed an undergraduate
degree or higher. 37.5% of the participants were married and one third were single or never
married (33.3%). Most of this sample (77.1%) considered themselves straight or
heterosexual. Participant characteristics in both groups were compared via independent
samples t tests for continuous variables, and c2 tests of independence for nominal and
categorical variables, but no differences were found.
2.2

Measures
2.2.1

DSM-5 Diagnoses

The Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive
and Related Neuropsychiatric Disorders (DIAMOND; Tolin et al., 2018) was used to
assess DSM-5 diagnoses for inclusion/exclusion criteria at baseline. The DIAMOND is a
semi-structured interview that assigns categorical DSM-5 diagnoses and dimensional
severity ratings (CSRs), using a scale between 1 (normal) and 7 (extreme). The
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DIAMOND has demonstrated very good (κ = .62) to excellent (κ = 1.00) interrater
reliability and good (κ = .59) to excellent (κ = 1.00) test-retest reliability on both
presence/absence of the diagnosis and severity rating; convergent validity was verified by
significant between-group comparisons on applicable self-report measures for nearly all
diagnoses (Tolin et al., 2018). Trained graduate students, who administered the
DIAMOND, demonstrated excellent reliability on categorical ratings of primary diagnoses
(Krippendorff’s αs: .91-1.00; median = 1.00) and CSRs of each disorder (Krippendorff’s
αs: .83-1.00; median = .92).
2.2.2

BPD Symptoms

Borderline personality disorder symptoms were assessed with the
Borderline Features Subscale from the Personality Assessment Inventory (PAI-BOR;
Morey, 1991) at baseline and all follow-up timepoints. This 24-item self-report scale
provides a total symptom score, as well as subscales for emotional problems assessed by
affect instability subscale (PAI-BOR-AI), relationship problems assessed by the
interpersonal relationships subscale (PAI-BOR-IR), identity problems assessed by identity
disturbance subscale (PAI-BOR-ID), and impulsivity assessed by the self-harm subscale
(PAI-BOR-SH). Both the construct and discriminant validity were established via
objective life-event data correlations (Slavin-Mulford et al., 2012). Concurrent validity
was also established, supporting the utility of PAI-BOR in assessing for BPD diagnosis
(Stein et al., 2007). The internal consistency of PAI-BOR items in the parent study at
baseline was acceptable (McDonald’s ω = .64).
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2.2.3

FFM Domains

The FFM domains were assessed by the NEO Five-Factor Inventory (NEOFFI; McCrae & Costa, 2004) at baseline and all follow-up timepoints. The NEO-FFI is a
60-item self-report measure with subscales for neuroticism, extraversion, agreeableness,
conscientiousness, and openness. The items are rated on a 5-point Likert scale, ranging
from strongly disagree to strongly agree. The internal consistencies reported for all
domains were good, ranging from .75 to .83 (Costa & McCrae, 1992). The internal
consistency of NEO-FFI items on the neuroticism subscale in the parent study at baseline
was good (McDonald’s ω = .82). Internal consistency of NEO-FFI items in the parent
study at baseline on the extraversion subscale was good (McDonald’s ω = .84), on the
agreeableness subscale was acceptable (McDonald’s ω = .60), on the conscientiousness
subscale was excellent (McDonald’s ω = .90), on the openness subscale was acceptable
(McDonald’s ω = .62).
2.3

Procedures
Procedures for the parent trial were approved by the University of Kentucky

Institutional Review Board. The study procedures were explained to participants and
informed consent was obtained prior to the start of the study. Following a baseline
assessment conducted by trained assessors at pre-treatment, participants were randomized
to either receive the standard delivery of the UP, compensation delivery in which the UP
modules were sequenced based on participants’ weaknesses, or capitalization delivery in
which the UP modules were sequenced based on participants’ strengths. After the fifth
treatment session, a second battery of assessments was administered to participants who
then underwent a second-stage randomization in which they were assigned to receive Brief
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(6 sessions) or Full (12 sessions) Treatment conditions. At the end of the Full Treatment,
the last battery of assessments was administered to all participants, regardless of the length
of the treatment they received, resulting in three major timepoints. All participants were
paid $25 for their time at the second and third assessment timepoints. All study data were
collected and managed using Research Electronic Data Capture (REDCap) tools hosted at
University of Kentucky (Harris et al., 2009, 2019).
2.4

Analytic Approach

2.4.1

Characterizing Change in BPD Symptoms During Treatment with the UP
In the case of missing data 1, listwise deletion was utilized to ensure data at

all timepoints in order to calculate within-person change scores across timepoints. Data
were collapsed across treatment sequencing conditions due to the lack of significant
differences in changes in clinical severity across people assigned to the standard,
compensation, or capitalization deliveries (Sauer-Zavala et al., under review). Descriptive
statistics and primary analyses were conducted in SPSS Version 27.0 (IBM Corp., 2020).
To test the hypotheses regarding the effect of UP treatment on the total BPD score and the
subscales Hedges’s g was calculated in both the full sample and the BPD subset. Hedges’s
g allows for the examination of the magnitude of change from the baseline assessment to
the second assessment (after five sessions of treatment), from baseline to the third
assessment, and from the second assessment to the third assessment 2. The Hedges’s g is a
preferable approach for analyses of treatment studies because it gives an unbiased estimate

1

Multiple imputation approach did not yield differences in the results and thus raw data were used for
analyses as a more conservative approach.
2 All participants received treatment between baseline and second assessment (A2). After A2, participants
were randomized to either discontinue after their 6th session or after their 12th session. Thus, some
participants received a single additional session between A2 and A3 and some received 7 additional
sessions.
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of the population effect size and is appropriate for small sample sizes (Lakens, 2013).
Additionally, between group effect sizes, using Hedges’s g, were calculated for BPD
symptoms at all study timepoints, comparing individuals assigned to the Full and Brief
Treatment conditions. Hedge’s g is interpreted using the same standards as Cohen's d (i.e.,
0.2, 0.5, and 0.8 reflecting small, medium, and large effects, respectively) and change on
variables of interest are considered statistically significant if the confidence intervals do
not include zero.
2.4.2

FFM Dimensions as Predictors of BPD Symptom Improvement
To explore whether FFM dimensions predict improvements BPD

symptoms, we conducted a set of hierarchical regression analyses in the full sample.
Specifically, we regressed BPD symptoms at assessment 2 (i.e., after 5 weeks of treatment)
on to baseline BPD symptoms and either neuroticism, agreeableness, or conscientiousness;
three separate regressions were conducted so that each FFM dimension was included in its
own model. We elected to examine BPD symptoms as assessment 2 in order to increase
our power to detect an effect given that all participants received treatment from baseline
to assessment 2.
Given that BPD symptoms were relatively low in the full sample (perhaps
creating a floor effect for improvements), along with the fact that there were only 9
individuals in our BPD subset, we conducted exploratory analyses to investigate whether
FFM profiles were related to within-individual change on BPD symptoms. First, we
examined within participant change on BPD symptoms from pre-treatment to assessment
2 and from pre-treatment to assessment 3. Significance of within participant change was
evaluated by calculating a 95% confidence interval (CI) around observed change scores to
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determine reliability of changes (see: Au et al., 2017); Jacobson and Truax's (1991) method
was used for calculating standard error of the difference (Sdiff). The Sdiff was calculated
as a square root of 2*(SE)2 in which the standard error (SE) was computed as SD*sqrt (1
– rxx). Standard deviation (SD = 13.85) and a reliability coefficient (rxx = 0.91) were taken
from normative data using the clinical sample in the PAI Professional Manual 2nd Edition
(Morey, 1991). Sdiff was then multiplied by 1.96 to create a 95% confidence interval (CI)
around each change score. When this 95% CI does not include zero, change is considered
statistically significant. Next, to examine whether FFM profiles affect the extent to which
individual participants respond to the UP, we graphically represented each patient’s FFM
scores at baseline. Participants were categorized into two groups: 1) high neuroticism
(average agreeableness and conscientiousness), and 2) low agreeableness and/or low
conscientiousness. High (T > 55) and low (T < 45) levels on these domains were
determined by computing t-scores for each participant’s raw score, using normative data
from the NEO-FFI-3 professional manual (Costa & McCrae, 1992). Finally, we examined
the proportion of participants in each personality profile group who demonstrated reliable
change on our measure of BPD symptoms.
2.5

Power
Given that this study is a secondary data analysis, a sensitivity analysis to

determine the strength of the effect that can be reliably detected was conducted (Faul et
al., 2007). Specifically, we conducted a sensitivity analysis regarding the hypotheses
regarding the effect of UP treatment on the total BPD score and the subscales. Based on a
sensitivity power analysis in G*Power Version 3.1 (Faul et al., 2009) assuming α = .05
(two-tailed), power = 0.80, total sample size = 9, the minimum effect size that could
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reliably yield a statistically significant result given this study’s sample size was d = 1.07.
Given the descriptive and exploratory nature of the third aim, investigating whether there
are differences in within-person change in BPD scores during treatment based on different
FFM profiles at baseline, power and sensitivity analyses were inappropriate and thus not
conducted.
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CHAPTER 3. RESULTS
3.1

Characterizing Change in BPD Symptoms During Treatment with the UP
Means and standard deviations for the PAI-BOR and each of its subscales

can be viewed in Table 1 for both the full sample and the BPD sample. Change was in the
expected direction from baseline to Assessment 2 (i.e., following 5 sessions of UP
treatment) in all but one instance (i.e., the full sample demonstrated a slight increase on
the Emotional Problems subscale). In general, any improvements were largely maintained
at Assessment 3 (i.e., after 12 sessions for individuals in the Full Treatment condition, after
a 6-week follow-up period for individuals in the Brief Treatment condition). Hedges’s g
was used to evaluate the magnitude of change on each variable; detailed information
concerning within-participants effect sizes between assessments are reported in Table 1.
In the full sample, the degree of change was minimal across all assessment points.
However, in the BPD subsample, the UP was associated with moderate reductions in total
BPD symptoms between assessments 1 and 2 and between assessments 1 and 3, along with
small reductions in the PAI-BOR subscales at these timepoints. Of note, the confidence
intervals for these effect size estimates included zero, suggesting that these within-group
improvements were not statistically significant (likely due to our small sample size).
Additionally, Hedges’s g was also calculated to determine the degree of
difference on BPD symptoms between the Full and Brief Treatment conditions at all time
points. The results are reported in Table 2. In line with expectations, there were no
significant differences between conditions at baseline (when no treatment had been
administered to either condition) or at assessment 2 (when patients in both conditions had
received 5 UP sessions), with two exceptions. Patients with BPD in the Full Treatment
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condition reported significantly lower symptoms of emotional problems than those in the
Brief Treatment condition at assessment 1; however, by assessment 2, these differences
were no longer significant. Similarly, patients with BPD in the Full Treatment condition
reported significantly lower symptoms of identity problems at assessment 2 relative to
patients in the Brief Treatment condition. With regard to our comparison of substantive
interest, comparing BPD symptoms at assessment 3 for patients who completed a full 12
session and patients who completed 6 sessions and a 6-week follow-up period, there were
no significant differences between groups. In the full sample, differences between
individuals in the Full Treatment condition and Brief treatment condition on overall BPD
symptoms, emotional problems, and relationship problems were small in magnitude,
favoring patients who received all 12 sessions. A similar pattern of results was
demonstrated for the BPD subset, yet differences between treatment length conditions
were moderate in magnitude for overall BPD symptoms, emotional problems, and
relationship problems, along with large differences for identity problems. Again,
confidence intervals for these effects included zero, indicating that they are not statistically
significant (again, likely due to small sample size).
3.2

FFM Dimensions as Moderators of BPD Symptom Improvement
Separate hierarchical multiple regression models were used to assess

whether FFM dimensions predict total BPD score at assessment 2 for the full sample, after
controlling for baseline total BPD scores (see Table 3). Baseline total BPD scores were
entered at Step 1 for each model, explaining 63.2% of the variance in total BPD scores at
assessment 2. In Step 2 of each model, agreeableness and conscientiousness were not
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significant predictors of the total BPD scores at assessment 2, whereas neuroticism was
marginally significant.
For our exploratory analyses investigating whether FFM profiles were
related to within-individual change on BPD symptoms, we first graphically represented
each patient’s BPD-relevant FFM scores (neuroticism, agreeableness, conscientiousness)
at baseline (see Figure 1). Using normative data from the NEO-FFI-3 professional manual,
all patients in the BPD subsample were categorized as exhibiting high neuroticism scores,
whereas five patients also endorsed low levels of conscientiousness. Of note, no patients
in our sample were classified as exhibiting low agreeableness.
Within-individual change on BPD symptoms for our BPD subsample are
depicted in Table 4; shaded rows represent individuals classified as exhibiting high
neuroticism and low conscientiousness, whereas non-shaded rows represent those that
endorsed high neuroticism, only. Across all 9 individuals, only three patients reported
statistically significant change scores between assessments; however, one of these
participants’ total BPD score increased from baseline to second assessment, and from
second assessment to third (see participant 5). Participant 3, who was in Full Treatment
condition, reported fourteen-points reduction in their overall BPD scores from baseline to
assessment 2 (statistically significant), but reported 3 points increase at assessment 3,
rendering their improvement no longer significant. Participant 9, from Brief Treatment
condition, reported significant decrease in their total BPD scores at assessment 3. Overall,
there were no discernable patterns in rates of improvement as a function of baseline FFM
scores.
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Table 1: Within Participant Effect Sizes for change in BPD Symptoms in the Full and BPD Subset Samples
Full Sample (N = 59)
BL

A2

BL to A2

A2 to A3

M

SD

Hedges'
g

0.01

[-0.16,
1.80]

28.82

10.91

0.02

[-0.17,
0.21]

0.06

[-0.08,
0.20]

3.58

-0.11

[-0.31,
0.10]

7.91

3.25

-0.06

[-0.27,
0.15]

0.06

[-0.11,
0.23]

7.86

3.47

0.09

[-0.09,
0.27]

8.23

3.97

-0.05

[-0.25,
0.16]

-0.08

[-0.24,
0.09]

3.05

9.00

3.88

0.02

[-0.17,
0.21]

8.49

3.84

0.18

[-0.05,
0.38]

0.02

[0.01,
0.39]

3.23

4.13

3.12

0.01

[-0.16,
0.17]

4.19

3.30

-0.01

[-0.14,
0.13]

-0.01

[-0.16,
0.15]

SD

29.16

9.66

29.09 10.41

Emotional
Problems

7.75

3.08

8.11

Relationship
Problems

8.18

3.62

Identity
Problems

9.09

Impulsivity

4.14

BPD Symptoms

BL to A3

95% CI

M

M

SD

Hedges'
g

A3

95% CI

Hedges'
g

95% CI

Subscales
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Table 1 (Continued)
BPD Subset (n = 9)
BL

A2

BL to A2

M

SD

M

SD

Hedges'
g

45.89

4.23

41.78

7.55

Emotional
Problems

12.00

2.40

11.44

Relationship
Problems

12.67

3.24

Identity
Problems

13.00

Impulsivity

8.22

BPD Symptoms

A3

BL to A3

A2 to A3

95% CI

M

SD

Hedges'
g

0.61

[-0.24,
1.45]

41.22

9.67

0.54

[-0.30,
1.39]

0.06

[-0.57,
0.69]

3.57

0.16

[-0.41,
0.73]

11.11

3.66

0.26

[-0.48,
1.00]

0.09

[-0.44,
0.62]

11.44

3.50

0.34

[-0.33,
1.02]

11.67

3.54

0.28

[-0.62,
1.19]

-0.06

[-0.66,
0.54]

2.35

12.00

3.97

0.27

[-0.40,
0.94]

11.44

4.48

0.37

[-0.32,
1.06]

0.12

[-0.27,
0.52]

3.90

6.89

3.86

0.33

[-0.03,
0.68]

7.00

4.42

0.26

[0.00,
0.52]

0.03

[-0.44,
0.39]

95% CI

Hedges'
g

95% CI

Subscales
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Table 2: Between Condition Effect Sizes for BPD Symptoms as a Function of Treatment Length
Full Sample
BL

A2
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Brief

Full

M
(SD)

M
(SD)

BPD
Symptoms

29.91
(9.92)

28.65
(9.03)

-0.13

Emotional
Problems

8.09
(3.54)

7.53
(2.54)

Relationship
Problems

8.65
(3.63)

Identity
Problems
Impulsivity

A3

Brief

Full

Brief

Full

95% CI

M
(SD)

M
(SD)

Hedges'
g

UL, LL

M
(SD)

M
(SD)

Hedges' UL, LL
g

[-0.60,
0.34]

30.00
(11.40)

28.48
(9.35)

0.14

[-0.37,
0.66]

30.31
(11.81)

27.00
(9.82)

0.30

[-0.21,
0.81]

0.18

[-0.30,
0.66]

8.40
(3.94)

7.85
(3.11)

0.15

[-0.36,
0.66]

8.45
(3.72)

7.34
(2.58)

0.34

[-0.17,
0.85]

7.74
(3.56)

0.25

[-0.22,
0.72]

8.37
(3.93)

7.41
(2.83)

0.27

[-0.24,
0.79]

9.14
(4.50)

7.17
(3.14)

0.50

[-0.02,
1.01]

9.47
(3.21)

8.79
(2.97)

0.22

[-0.26,
0.69]

9.47
(4.09)

8.59
(3.61)

0.22

[-0.29,
0.74]

8.76
(4.15)

8.10
(3.53)

0.17

[-0.34,
0.68]

3.71
(2.92)

4.59
(3.70)

-0.26

[-0.73,
0.21]

3.77
(2.90)

4.63
(3.34)

-0.27

[-0.79,
0.24]

3.97
(3.42)

4.38
(3.17)

-0.12

[-0.63,
0.39]

95% CI

Hedges'
UL, LL
g

95% CI

Table 2 (Continued)
BPD Subset
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BPD
Symptoms

46.80
(4.76)

44.75
(3.77)

0.42

[-0.88,
1.79]

46.00
(5.700)

36.50
(6.45)

1.40

[-0.01,
2.73]

44.60
(9.40)

37.00
(9.42)

0.72

[-0.53,
1.92]

Emotional
Problems

13.40
(1.95)

10.25
(1.71)

1.51

[0.07,
2.88]

12.80
(3.56)

9.75
(3.20)

0.79

[-0.47,
2.01]

12.20
(4.60)

9.75
(1.71)

0.60

[-0.63,
1.78]

Relationship
Problems

12.80
(3.70)

12.50
(3.11)

0.08

[-1.09,
1.24]

12.80
(3.96)

9.75
(2.22)

0.81

[-0.45,
2.03]

12.60
(4.16)

10.50
(2.65)

0.52

[-0.70,
1.70]

Identity
Problems

13.60
(1.52)

12.25
(3.20)

0.50

[-0.71,
1.68]

14.60
(2.07)

8.75
(3.30)

1.95

[0.37,
3.44]

13.80
(3.63)

8.50
(3.87)

1.26

[-0.11,
2.56]

Impulsivity

7.00
(3.94)

9.75
(3.77)

-0.63

[-1.82,
0.60]

5.80
(3.70)

8.25
(4.11)

-0.56

[-1.75,
0.66]

6.00
(5.15)

8.25
(3.59)

-0.44

[-1.61,
0.77]

Table 3: Baseline FFM Domains as Predictors of BPD Symptom Change in the Full Sample
B

SE

ß

p

Neuroticism

0.26

0.13

0.18

0.053

Agreeableness

-0.20

0.18

-0.10

0.270

Conscientiousness

0.08

0.10

0.07

0.428

Note: Dependent variable is BPD symptoms at A2. In addition to the FFM domain (entered
at step 2), BPD symptoms at baseline is entered at step 1 as a predictor in each regression
model
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Table 4: Within-Individual Change in BPD Symptoms for the BPD Subsample
BPD Symptoms
95% CI = CS ± 11.52
Pre-treatment
Post-treatment
Post-treatment
Change Score A1- Change Score A1(A1)
(A2)
(A3)
A2
A3
(95% CI)
(95% CI)
Patient 1†
45.00
41.00
34.00
-4.00
-11.00
(-15.52, 7.52)
(-22.52, .52)
Patient 2†
50.00
42.00
51.00
-8.00
1.00
(-19.52, 3.52)
(-10.52, 12.52)
Patient 3†
42.00
28.00
31.00
-14.00*
-11.00
(-25.52, -2.48)
(-22.52, .52)
Patient 4†
42.00
35.00
32.00
-7.00
-10.00
(-18.52, 4.52)
(-21.52, 21.52)
Patient 5
42.00
53.00
54.00
11.00
12.00*
(-.52, 22.52)
(.48, 23.52)
Patient 6
44.00
40.00
45.00
-4.00
1.00
(-15.52, 7.52)
(-10.52, 12.52)
Patient 7
49.00
42.00
49.00
-7.00
0.00
(-18.52, 4.52)
(-11.52, 11.52)
Patient 8
54.00
51.00
46.00
-3.00
-8.00
(-14.52, 8.52)
(-19.52, 3.52)
Patient 9
45.00
44.00
29.00
-1.00
-16.00*
(-12.52, 10.52)
(-27.52, -4.48)
Note. †Patient was in full treatment condition. *Denotes significant change score. Participants with high neuroticism and low
conscientiousness are displayed in shaded rows. The confidence intervals were computed using data from the clinical sample in
the PAI Professional Manual 2nd Edition. The high and low values of neuroticism, agreeableness, and low conscientiousness
domains were computed from the normative data of the NEO-FFI-3 professional manual.
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Figure 1: Baseline FFM profile of Patient 1
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Figure 2: Baseline FFM profile of Patient 2
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Figure 3: Baseline FFM profile of Patient 3
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Figure 4: Baseline FFM profile of Patient 4
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Figure 5: Baseline FFM profile of Patient 5
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Figure 6: Baseline FFM profile of Patient 6
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Figure 7: Baseline FFM profile of Patient 7
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Figure 8: Baseline FFM profile of Patient 8
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Figure 9: Baseline FFM profile of Patient 9
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Agreeableness

CHAPTER 4. DISCUSSION
The purpose of the present study was to explore the utility of the Unified
Protocol (UP) with treatment of borderline personality disorder (BPD) and whether there
are factors that may affect BPD symptom improvements during treatment. Patients with
principal anxiety (social anxiety disorder, generalized anxiety disorder, panic disorder),
depressive (major depressive disorder, persistent depressive), or related (obsessivecompulsive disorder, posttraumatic stress disorder) disorders received 6 or 12 sessions of
the UP. A subset of our sample (9 individuals) likely met criteria for comorbid BPD. Given
that previous research has demonstrated significant improvements in BPD symptoms
during treatment with the UP (e.g., Lopez et al., 2015; Sauer-Zavala et al., 2016), we
anticipated similar effects in this study as well. Contrary to expectations, improvements in
total BPD symptoms were not observed in the full sample, likely due to floor effects
(scores on the PAI-BOR were quite low in our sample, overall). However, among
participants who likely met criteria for this condition, our first hypothesis was partially
supported such that the UP resulted in moderate overall BPD symptom improvement,
though these changes were not statistically significant.
One possible explanation for the disparity between the present study’s
findings and previous research on applying the UP in BPD samples is that prior work (e.g.,
Lopez at al., 2015; Sauer-Zavala et al., 2016) specifically recruited participants with BPD
diagnoses. Given that these studies were explicitly designed to test the effect of the UP for
BPD, it is likely that therapists were more compelled to specifically apply UP skills to
BPD symptoms. Indeed, in Lopez et al. (2015) study, “the UP specifically targeted
borderline symptomatology.” On the other hand, the present study recruited participants
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based on anxiety or depressive disorders; BPD symptoms were not assessed on clinicianrated instruments, so study therapists were likely unaware that some of their patients had
comorbid BPD. In other words, despite BPD symptoms being functionally related to the
targets of the UP, therapists might not have asked about/targeted them in treatment.
Perhaps, for the UP to replicate efficacy with BPD from the abovementioned studies, the
clinicians need to make a point to use UP skills specifically for BPD symptoms.
Additionally, the length of the treatment in this study was shorter compared
to other brief interventions. It is possible that the treatment length was simply not sufficient
for reductions in BPD symptoms. In the current study, participants underwent 6 (Brief) or
12 (Full) weeks of treatment. The treatment in the extant studies, mentioned in the
introduction, focusing specifically on the efficacy of the UP with BPD, lasted between 14
and 29 weekly session (Lopez et al., 2015; Sauer-Zavala et al., 2016; Tonarely et al., 2020).
Furthermore, a recent meta-analysis reviewing randomized controlled trials (RCTs) of
brief BPD interventions (Spong et al., 2021) revealed that although brief interventions may
be effective, no direct conclusions can be made about the long-term impact of those
interventions. Notably, all RCTs reviewed in this meta-analysis were between three and
six months long, suggesting that short-term BPD treatments might be useful, but there is a
minimum timeframe required for the length of treatment. There was one study of patients
with BPD in which significant reductions in depression, impulsivity, self-esteem, emotion
regulation, self-harm, and suicidality were noted only after 12 weeks of group and
individual therapy that integrated components of dialectical behavior therapy,
mentalization-based therapy, and other structured treatments (Laporte et al., 2018).
However, their outcomes did not include BPD symptom severity. Lastly, there is dearth in
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the literature about BPD treatments as short as 12 sessions and as such, we cannot conclude
whether 12 weekly sessions were enough to produce significant results in reductions of
BPD symptoms.
Given that the UP purports to target negative emotionality, we anticipated
larger reductions in the emotional problems subscale of the PAI-BOR relative to the other
subscales. Our second hypothesis was not supported such that, although minimal, a larger
degree of change was observed for identity problems, relationship problems, and
impulsivity relative to emotional difficulties between baseline and assessments 2 and 3. It
is possible that emotional problems measured by the subscale of affective instability, such
as sudden mood changes (which can be negative), might not be well represented by
neuroticism targeted by the UP. Also, given that there were no statistically significant
improvements in BPD symptoms in this sample overall or in the BPD subsample, the effect
of the UP on emotional problems could have been diluted. Lastly, the confidence intervals
of the computed effect sizes in all subscales were somewhat similar in ranges, and thus we
cannot draw sound conclusions about which subscale improved the most.
Next, we sought to explore whether FFM traits at baseline were associated
with treatment response to the UP. Extant personality disorder research suggests that BPD
can be understood as elevations in neuroticism, along with low levels of agreeableness and
conscientiousness (e.g., Mullins-Sweatt et al., 2012). Given that the UP was developed to
address neuroticism, we hypothesized that individuals endorsing low levels of
agreeableness and/or conscientiousness would not respond as well to this intervention.
Using the full sample to increase our power, regression analyses suggested that change on
BPD symptoms from baseline to assessment 2 (i.e., following five sessions of the UP) was

32

not predicted by baseline levels of agreeableness, or conscientiousness – contrary to
expectations. Neuroticism demonstrated a trend towards significance (p = .053),
suggesting that higher baseline levels of this trait are associated with less improvement in
BPD symptoms. This finding appears to be consistent with a body of research documenting
that higher levels of neuroticism predict poorer outcomes in depressive disorders (e.g.,
Bock et al., 2010; Hayden & Klein, 2001; Quilty et al., 2008). It is possible then that the
already high levels of neuroticism in the current sample precluded improvements in BPD
symptoms.
Given that the full sample did not endorse a high degree of BPD symptoms,
we sought to explore whether baseline personality profiles of patients in our BPD subset
could be used to predict treatment response. For patients classified as exhibiting high
neuroticism (and at least moderate levels of agreeableness and conscientiousness), three
out of four participants (75%) demonstrated reductions in BPD symptoms from baseline
to assessment 2, and these improvements continued to grow by assessment 3 (of note, only
one of these participants was in the Full Treatment condition). Although all five
participants with high neuroticism and low conscientiousness experienced reductions of
BPD symptoms from baseline to assessment 2, only one of these participants (20%)
continued experiencing reduction in BPD symptoms by assessment 3. In contrast, four out
of five participants (80%) with high levels of neuroticism and low levels of
conscientiousness exhibited worsening symptoms from assessment 2 to assessment 3.
Thus, our hypothesis regarding within-person change in BPD scores based on patients’
FFM profiles was partially supported. Individuals with FFM profiles characterized by low
conscientiousness may exhibit early gains in treatment but are unable to sustain them
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across a longer period of time, suggesting the need to engage in this trait in a
comprehensive treatment for BPD. Additionally, as we already mentioned, the duration of
the treatment (i.e., 6 or 12 sessions) might have simply not sufficed to treat BPD symptoms
effectively.
While this study conveys important information about the utility of the UP
in treatment of BPD, there are several important limitations that need to be addressed.
Given that this was a secondary analysis project with a relatively small sample size, we
were underpowered for regression analyses as well as unlikely to detect significant effects
in magnitudes of change. Additionally, the number of participants who likely met criteria
for BPD was also small, as the parent study’s inclusion criteria did not include BPD
diagnosis, and thus our analyses were not powered to detect change. It is also important to
note that the BPD disorder was not assessed by the Structured Clinical Interview for DSMIV Axis II Disorders (SCID-II; First & Gibbon, 2004) which would yield accurate
diagnosis. Instead, a total score of 38 or higher (equivalent to 65T) on the self-reported
Personality Assessment Inventory-Borderline Features Subscale (PAI-BOR; Morey,
1991) was used to identify participants who would likely meet the criteria for BPD
diagnosis. Although this instrument has been reasonably reliable in identifying individuals
with BPD, it might have not been as accurate as a structured clinical assessment. Further,
our findings may not be generalizable to individuals not seeking treatment for anxiety,
depressive, and related disorders.
Despite the limitations in this study, this manuscript is an important step in
defining the utility of the Unified Protocol with patients with BPD. Specifically, when
comorbid with anxiety, depressive, and related disorders. In sum, individuals with BPD
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experienced small to moderate, yet not statistically significant, improvements in their
symptoms. However, the participants with BPD who mapped onto the typical FFM profile
of BPD did not sustain these improvements in the long term. As such, the UP may be
helpful in treating comorbid BPD symptoms in the short term, but to achieve large and
sustained improvements, clinicians ought to focus on the BPD symptomology as a primary
target and prioritize agreeableness and conscientiousness traits as well.
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